Cellectis SA ADR CLLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CLLS is a good fit for your portfolio.
News
-
AMD, Kraft Heinz stocks surge, WeWork and CVS shares sink and other stocks on the move
-
Cellectis Shares Soar Premarket on AstraZeneca Deal
-
Cellectis' stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca
-
AstraZeneca to Invest $245 Million in Deal With Cellectis
Trading Information
- Previous Close Price
- $2.55
- Day Range
- $2.59–2.65
- 52-Week Range
- $0.96–3.77
- Bid/Ask
- $2.53 / $2.70
- Market Cap
- $189.96 Mil
- Volume/Avg
- 23,573 / 36,681
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.39
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 236
- Website
- https://www.cellectis.com
Comparables
Valuation
|
Metric
|
CLLS
|
IPH
|
FUSN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.93 | 3.37 | 7.64 |
Price/Sales | 8.39 | 3.36 | 676.42 |
Price/Cash Flow | — | — | — |
Price/Earnings
CLLS
IPH
FUSN
Financial Strength
|
Metric
|
CLLS
|
IPH
|
FUSN
|
|---|---|---|---|
Quick Ratio | 2.03 | 3.51 | 14.66 |
Current Ratio | 2.20 | 3.73 | 15.01 |
Interest Coverage | −16.29 | −15.79 | −19.06 |
Quick Ratio
CLLS
IPH
FUSN
Profitability
|
Metric
|
CLLS
|
IPH
|
FUSN
|
|---|---|---|---|
Return on Assets (Normalized) | −33.65% | −2.51% | −33.14% |
Return on Equity (Normalized) | −76.48% | −9.04% | −43.87% |
Return on Invested Capital (Normalized) | −41.29% | −7.88% | −36.42% |
Return on Assets
CLLS
IPH
FUSN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gslprpbxfw | Bmw | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mfpmcxgyr | Xghfhp | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ylgxxynrw | Vqqdvnm | $98.8 Bil | |
MRNA
| Moderna Inc | Yzpgnwwf | Wcll | $38.8 Bil | |
ARGX
| argenx SE ADR | Xtslypbrq | Qfyw | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Tsvvqgtwh | Nlx | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dcjxlnw | Hzmlf | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jhspqbwd | Tlkbq | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bbflcwmrjg | Rbdtfvm | $12.4 Bil | |
INCY
| Incyte Corp | Rypfbkc | Mcxsbx | $11.9 Bil |